The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload

BackgroundPulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary artery pressure leading to right ventricular (RV) failure. While current PAH therapies improve patient outlook, they show limited benefit in attenuating RV dysfunction. Recent investigations...

Cijeli opis

Bibliografski detalji

Glavni autori:	Eamon P. Mulvaney, Fabiana Renzo, Rui Adão, Emilie Dupre, Lucia Bialesova, Viviana Salvatore, Helen M. Reid, Glória Conceição, Julien Grynblat, Aida Llucià-Valldeperas, Jean-Baptiste Michel, Carmen Brás-Silva, Charles E. Laurent, Luke S. Howard, David Montani, Marc Humbert, Anton Vonk Noordegraaf, Frédéric Perros, Pedro Mendes-Ferreira, B. Therese Kinsella
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2022-12-01
Serija:	Frontiers in Cardiovascular Medicine
Teme:	pulmonary arterial hypertension (PAH) thromboxane receptor NTP42 right ventricle (RV) heart failure
Online pristup:	https://www.frontiersin.org/articles/10.3389/fcvm.2022.1063967/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!